GLP-1 weight loss drugs linked to nail and hair loss
Ozempic and Wegovy are known for dramatic weight loss, but researchers are flagging an unexpected side effect. Users report significantly higher rates of nail detachment, hair loss, and scalp inflammation. And weight loss alone does not seem to explain it.
GLP-1 receptor agonists are drugs that mimic a gut hormone to suppress appetite. They have become widely prescribed for obesity and type 2 diabetes. Nausea and digestive side effects are already well documented. But problems with nails and hair had not previously been flagged so systematically.
More than the weight coming off
Researchers analysed adverse event reports from users of popular GLP-1 medications. They found that onycholysis (nail detachment from the nail bed) and hair loss occurred several times more frequently than would be expected in the general population, according to the research. Scalp inflammation was also reported more often.
Critically, the researchers calculated that weight loss alone could not fully account for the higher rates. This suggests the medications themselves may play a direct role in these effects, independent of the weight reduction. The precise mechanism has not yet been identified.
Why this matters for older users
GLP-1 drugs are increasingly used by older adults, partly because of their potential protective effects on the heart and brain. But nail and hair health are also indicators of general physical condition. Nail detachment and scalp inflammation can affect quality of life and deserve attention during long-term use. These findings are based on reported side effects and are preliminary. Randomised trials are needed to establish a causal link.
For people already using or considering these medications, the researchers emphasise the importance of discussing less obvious complaints openly with a doctor.
Search terms to explore further: GLP-1 agonist adverse effects dermatological | onycholysis drug-induced | hair loss pharmacological mechanism